Royalty Pharma plc (RPRX)
NASDAQ: RPRX · IEX Real-Time Price · USD
30.54
+0.09 (0.28%)
Mar 28, 2024, 9:51 AM EDT - Market open

Royalty Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
2,3552,2372,2892,1221,8141,7951,598
Revenue Growth (YoY)
5.24%-2.28%7.87%16.98%1.08%12.33%-
Gross Profit
2,3552,2372,2892,1221,8141,7951,598
Selling, General & Admin
249.75227.3182.83181.72103.4461.91106.44
Research & Development
52177.11200.0826.2983.04392.61117.87
Other Operating Expenses
560.661,526475.84318.95-995.4-24.07433.93
Operating Expenses
862.41,930858.75526.95-808.92430.45658.24
Operating Income
1,492307.071,4311,5952,6231,364939.69
Interest Expense / Income
187.19187.96166.14157.06268.57279.96247.34
Other Expense / Income
170.1376.27644.85463.36.07-293.24-517.67
Pretax Income
1,13542.83619.73975.042,3491,3781,210
Net Income
1,13542.83619.73975.042,3491,3781,210
Net Income Growth
2549.50%-93.09%-36.44%-58.48%70.46%13.86%-
Shares Outstanding (Basic)
448438415375595--
Shares Outstanding (Diluted)
603438415375---
Shares Change
37.66%5.59%10.48%-36.94%---
EPS (Basic)
2.540.101.491.32---
EPS (Diluted)
2.530.101.491.32---
EPS Growth
2430.00%-93.29%12.88%----
Free Cash Flow
2,9752,1441,9992,0351,4171,6181,418
Free Cash Flow Per Share
6.654.894.825.422.38--
Dividend Per Share
0.8000.7600.6800.300---
Dividend Growth
5.26%11.76%126.67%----
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
63.37%13.73%62.49%75.17%144.59%76.02%58.81%
Profit Margin
48.20%1.91%27.07%45.94%129.45%76.76%75.72%
Free Cash Flow Margin
126.37%95.83%87.31%95.87%78.12%90.16%88.76%
EBITDA
1,322230.79785.871,1322,6171,6581,457
EBITDA Margin
56.15%10.32%34.33%53.34%144.25%92.36%91.20%
EBIT
1,322230.79785.871,1322,6171,6581,457
EBIT Margin
56.15%10.32%34.33%53.34%144.25%92.36%91.20%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).